Molecular Oncology
Volume 2, Issue 1 , Pages 54-69 , June 2008

Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells

  • Yutaka Hasegawa

      Affiliations

    • Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, United States
    • These authors contributed equally to this manuscript.
    • ,
  • Mandi Murph

      Affiliations

    • Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, United States
    • Corresponding Author InformationCorresponding author.
    • These authors contributed equally to this manuscript.
    • ,
  • Shuangxing Yu

      Affiliations

    • Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, United States
    • ,
  • Gabor Tigyi

      Affiliations

    • Department of Physiology, The University of Tennessee Health Science Center, 894 Union Avenue, Memphis, TN 38163, United States
    • ,
  • Gordon B. Mills

      Affiliations

    • Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, United States
    • Tel.: +1 713 563 4212; fax: +1 713 563 4235.

Received 13 December 2007 ,Revised 27 March 2008 ,Accepted 28 March 2008.

References 

  1. An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. The Journal of Biological Chemistry. 1998;273(14):7906–7910
  2. An S, Tsai C, Goetzl EJ. Cloning, sequencing and tissue distribution of two related G protein-coupled receptor candidates expressed prominently in human lung tissue. FEBS Letters. 1995;375(1–2):121–124
  3. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, et al. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. The Journal of Biological Chemistry. 2006;281(32):22786–22793
  4. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure–activity relationship of cloned LPA receptors. FEBS Letters. 2000;478(1–2):159–165
  5. Barzik M, Kotova TI, Higgs HN, Hazelwood L, Hanein D, Gertler FB, et al. Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. The Journal of Biological Chemistry. 2005;280(31):28653–28662
  6. Bian D, Mahanivong C, Yu J, Frisch SM, Pan ZK, Ye RD, et al. The G(12/13)-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration. Oncogene. 2005;
  7. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biology. 2006;7(10):R100
  8. Chan LC, Peters W, Xu Y, Chun J, Farese RV, Cases S. LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). Journal of Leukocyte Biology. 2007;82(5):1193–1200
  9. Chen M, Towers LN, O'Connor KL. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. American Journal of Physiology. 2007;292(5):C1927–C1933
  10. Chettibi S, Lawrence AJ, Stevenson RD, Young JD. Effect of lysophosphatidic acid on motility, polarisation and metabolic burst of human neutrophils. FEMS Immunology and Medical Microbiology. 1994;8(3):271–281
  11. Chitaley K, Chen L, Galler A, Walter U, Daum G, Clowes AW. Vasodilator-stimulated phosphoprotein is a substrate for protein kinase C. FEBS Letters. 2004;556(1–3):211–215
  12. Dertsiz L, Ozbilim G, Kayisli Y, Gokhan GA, Demircan A, Kayisli UA. Differential expression of VASP in normal lung tissue and lung adenocarcinomas. Thorax. 2005;60(7):576–581
  13. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clinical Cancer Research. 2000;6(6):2482–2491
  14. Erickson JR, Hasegawa Y, Fang X, Eder A, Mao M, Furui T, et al. Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management. Prostaglandins. 2001;64(1–4):63–81
  15. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Annals of the New York Academy of Sciences. 2000;905:188–208
  16. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochimica et Biophysica Acta. 2002;1582(1–3):257–264
  17. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. The Journal of Biological Chemistry. 2004;279(10):9653–9661
  18. Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Letters. 2003;192(2):161–169
  19. Gov NS, Gopinathan A. Dynamics of membranes driven by actin polymerization. Biophysical Journal. 2006;90(2):454–469
  20. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. The Journal of Biological Chemistry. 2004;279(17):17634–17639
  21. Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G, et al. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochimica et Biophysica Acta. 2007;1771(7):883–892
  22. Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, et al. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. The Journal of Biological Chemistry. 2003;278(14):11962–11969
  23. Howe AK, Hogan BP, Juliano RL. Regulation of vasodilator-stimulated phosphoprotein phosphorylation and interaction with Abl by protein kinase A and cell adhesion. The Journal of Biological Chemistry. 2002;277(41):38121–38126
  24. Iwasaki T, Nakata A, Mukai M, Shinkai K, Yano H, Sabe H, et al. Involvement of phosphorylation of Tyr-31 and Tyr-118 of paxillin in MM1 cancer cell migration. International Journal of Cancer. 2002;97(3):330–335
  25. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians. 2007;57(1):43–66
  26. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, Gajewiak J, et al. alpha-Substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem. 2007;2(5):679–690
  27. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, et al. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Research. 2006;66(16):7983–7990
  28. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. The Journal of Biological Chemistry. 2006;281(25):17492–17500
  29. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, et al. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. The Journal of Pharmacology and Experimental Therapeutics. 2006;318(2):619–628
  30. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G(12/13)- and G(q)-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. The Journal of Biological Chemistry. 2006;281(33):23589–23597
  31. Levine JS, Koh JS, Triaca V, Lieberthal W. Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. The American Journal of Physiology. 1997;273(4 Pt 2):F575–F585
  32. Lu J, Xiao YJ, Baudhuin LM, Hong G, Xu Y. Role of ether-linked lysophosphatidic acids in ovarian cancer cells. Journal of Lipid Research. 2002;43(3):463–476
  33. Manning TJ, Parker JC, Sontheimer H. Role of lysophosphatidic acid and rho in glioma cell motility. Cell Motility and the Cytoskeleton. 2000;45(3):185–199
  34. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(1):131–136
  35. Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treatment and Research. 2002;107:259–283
  36. Mukai M, Imamura F, Ayaki M, Shinkai K, Iwasaki T, Murakami-Murofushi K, et al. Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA). International Journal of Cancer. 1999;81(6):918–922
  37. Murakami-Murofushi K, Mukai M, Kobayashi S, Kobayashi T, Tigyi G, Murofushi H. A novel lipid mediator, cyclic phosphatidic acid (cPA), and its biological functions. Annals of the New York Academy of Sciences. 2000;905:319–321
  38. Murph M, Tanaka T, Liu S, Mills GB. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clinical Cancer Research. 2006;12(22):6598–6602
  39. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. The Journal of Biological Chemistry. 2003;278(28):25600–25606
  40. O'Connor KL, Mercurio AM. Protein kinase A regulates Rac and is required for the growth factor-stimulated migration of carcinoma cells. The Journal of Biological Chemistry. 2001;276(51):47895–47900
  41. Panetti TS, Mosher DF. Lysophospholipid-induced cell migration. Annals of the New York Academy of Sciences. 2000;905:326–329
  42. Park SY, Schinkmann KA, Avraham S. RAFTK/Pyk2 mediates LPA-induced PC12 cell migration. Cellular Signalling. 2006;18(7):1063–1071
  43. Pasternack SM, von Kugelgen I, Aboud KA, Lee YA, Ruschendorf F, Voss K, et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nature Genetics. 2008;40(3):329–334
  44. Profirovic J, Gorovoy M, Niu J, Pavlovic S, Voyno-Yasenetskaya T. A novel mechanism of G protein-dependent phosphorylation of vasodilator-stimulated phosphoprotein. The Journal of Biological Chemistry. 2005;280(38):32866–32876
  45. Ridley AJ, Hall A. Signal transduction pathways regulating Rho-mediated stress fibre formation: requirement for a tyrosine kinase. The Embo Journal. 1994;13(11):2600–2610
  46. Rottner K, Behrendt B, Small JV, Wehland J. VASP dynamics during lamellipodia protrusion. Nature Cell Biology. 1999;1(5):321–322
  47. Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Research. 2002;62(21):6015–6020
  48. Shida D, Kitayama J, Yamaguchi H, Okaji Y, Tsuno NH, Watanabe T, et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Research. 2003;63(7):1706–1711
  49. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. The Journal of Biological Chemistry. 1992;267(4):2524–2529
  50. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochemical and Biophysical Research Communications. 2007;363(3):861–866
  51. Tigyi G, Fischer DJ, Sebok A, Marshall F, Dyer DL, Miledi R. Lysophosphatidic acid-induced neurite retraction in PC12 cells: neurite-protective effects of cyclic AMP signaling. Journal of Neurochemistry. 1996;66(2):549–558
  52. Uchiyama A, Mukai M, Fujiwara Y, Kobayashi S, Kawai N, Murofushi H, et al. Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid. Biochimica et Biophysica Acta. 2007;1771(1):103–112
  53. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of Cell Biology. 2002;158(2):227–233
  54. Valentine WJ, Fujiwara Y, Tsukahara R, Tigyi G. Lysophospholipid signaling: beyond the EDGs. Biochimica et Biophysica Acta. 2007;
  55. Van Leeuwen FN, Olivo C, Grivell S, Giepmans BN, Collard JG, Moolenaar WH. Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. The Journal of Biological Chemistry. 2003;278(1):400–406
  56. Xu J, Lai YJ, Lin WC, Lin FT. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. The Journal of Biological Chemistry. 2004;279(11):10459–10468
  57. Zaslavsky A, Singh LS, Tan H, Ding H, Liang Z, Xu Y. Homo- and hetero-dimerization of LPA/S1P receptors, OGR1 and GPR4. Biochimica et Biophysica Acta. 2006;1761(10):1200–1212

PII: S1574-7891(08)00042-2

doi: 10.1016/j.molonc.2008.03.009

Molecular Oncology
Volume 2, Issue 1 , Pages 54-69 , June 2008

Article Tools

* Image Usage & Resolution